Amgen’s $840m wager on Dark Blue shows why pharma keeps paying to make proteins disappear Obesity’s next arms race: staying power, not just weight loss Novartis’s $1.7bn Alzheimer’s bet: the real battleground is the blood–brain barrier Sanofi’s $2.2bn Dynavax deal — and the quiet power of adult vaccines The GLP-1 pill arrives: Novo’s oral Wegovy reshapes the obesity market Chai Discovery’s $130m bet: can “CAD for molecules” make biologics faster and cheaper? From Cow-Free Dairy to Human Milk 2.0: Biotechs Race to Brew Breast Milk Proteins When the FDA Starts Trusting Algorithms: What AIM-NASH Means for Liver Drug Trials The FDA wants to “pre-check” factories before the medicine exists The anti-ageing bet on the liver: why longevity biotech’s first real drugs may start here From California to Manchester: How One Gene Therapy Is Rewriting Hunter Syndrome Care A pill to live to 150? China’s grapeseed longevity hype gets right — and wrong A one-time gene edit for cholesterol: promise, price and the risks we can’t yet see From California to Manchester: How One Gene Therapy Is Rewriting Hunter Syndrome Care The explainable aging clock regulators might actually like The Billionaire Longevity Experiment: A Cruise Ship Promises to Extend Life—For a Price The anti-ageing bet on the liver: why longevity biotech’s first real drugs may start here The AI science factory arrives: why Lila’s $1.3bn valuation matters beyond biotech Galapagos quits cell therapy. Europe’s CGT reckoning begins. Sanofi’s $2.2bn Dynavax deal — and the quiet power of adult vaccines Roche’s Bold Foray into Obesity Treatment: A $5.3 Billion Bet on Petrelintide Revolutionizing Dairy: How Biotech Companies are Producing Milk Without Cows Researchers Awarded $15 Million to Study Impact of Inflammation on Heart and Brain Base & Prime Editing Move from Hype to Timelines: What Hits Patients 2026–2030? The hypertension reset: a daily aldosterone blocker meets a twice-yearly gene-silencer The patch that could unstick vaccination: Vaxxas’s A$90m bet on needle-free delivery From Hope to Proof: How Prasad’s FDA Could Reshape Biotech Approvals From Platform to Precision: The $800M Bet Transforming Biotech Investing More Than a Shot: Sanofi’s Vicebio Deal Shows the Power of Platform Biotech EU’s €12.5M Bet on Oncomatryx and Antibody-Drug Conjugates (ADCs) Gene Editing for Everyone: CRISPRware and the Open-Source Biotech Revolution Texas Ban on Lab-Grown Meat Triggers Policy and Legal Showdowns From Early Detection to Tumor “Education”: Syantra’s Bold Bet on cfRNA in Cancer Tech €132M for a Dutch Rare-Disease Upstart: Is Europe Quietly Becoming the New Neurology Capital? From Crypto to Cytoplasm: Brian Armstrong’s NewLimit Targets Hepatocytes for Anti-Aging Breakthrough Fermenting the Future: Inside the Pentagon’s $80 Million Biomanufacturing Bet—and America’s New Industrial Strategy Decoding the 100-Year-Old Code: Inside an Ambitious Quest to Unveil the Genetics of Extreme Longevity Cholesterol Rewritten: Verve’s Base Editing Therapy May Disrupt a $20B Market A Champion Departs: Peter Marks’ Resignation and Biotech’s Crossroads From Collapse to Comeback: Inside Biotech’s ‘Death-to-Rebirth’ Cycle Syngene’s Baltimore Bet: Indian Biotech’s American Ambitions and Global Supply Shake-Up Roche’s Bold Foray into Obesity Treatment: A $5.3 Billion Bet on Petrelintide Breaking the Bias: How Precision Medicine Can Overcome Ancestral Disparities STORIES WE THINK YOU MIGHT LIKE The Billionaire Longevity Experiment: A Cruise Ship Promises to Extend Life—For a Price Tropic Unveils Gene-Edited Non-Browning Bananas to Reduce Food Waste AbbVie Enters Obesity Drug Market with $2.2B Gubra Licensing Deal How AI is Revolutionizing Antibiotic Discovery to Combat Drug-Resistant Bacteria Metsera’s Weight-Loss Drug MET-097i Shows Strong Clinical Results Michigan-Based Biotech Startup CircNova Secures $3.3M Seed Funding to Advance AI-Driven Circular RNA Therapies AbbVie Enters Obesity Drug Market with $2.2B Gubra Licensing Deal How AI is Revolutionizing Antibiotic Discovery to Combat Drug-Resistant Bacteria Metsera’s Weight-Loss Drug MET-097i Shows Strong Clinical Results Michigan-Based Biotech Startup CircNova Secures $3.3M Seed Funding to Advance AI-Driven Circular RNA Therapies Illumina’s Market Struggles Deepen as U.S.-China Tensions Escalate MOST POPULAR From Early Detection to Tumor “Education”: Syantra’s Bold Bet on cfRNA in Cancer Tech Dermatology’s next play: bispecifics that shut down OX40L and TNF Base & Prime Editing Move from Hype to Timelines: What Hits Patients 2026–2030? The hypertension reset: a daily aldosterone blocker meets a twice-yearly gene-silencer The patch that could unstick vaccination: Vaxxas’s A$90m bet on needle-free delivery From Hope to Proof: How Prasad’s FDA Could Reshape Biotech Approvals From Platform to Precision: The $800M Bet Transforming Biotech Investing More Than a Shot: Sanofi’s Vicebio Deal Shows the Power of Platform Biotech EU’s €12.5M Bet on Oncomatryx and Antibody-Drug Conjugates (ADCs) Gene Editing for Everyone: CRISPRware and the Open-Source Biotech Revolution Texas Ban on Lab-Grown Meat Triggers Policy and Legal Showdowns Pfizer’s $4.9bn Metsera bet: can amylin finally tame GLP-1’s ‘GI tax’? Aging Science The explainable aging clock regulators might actually like Impact of Space Travel on Immune Function and Potential Countermeasures Debate Highlights: Can Aging Be Halted or Reversed? Experts Weigh In Epigenetic Stability Linked to Lifespan in Mammals, Research Show New Study Highlights the Impact of Early-Life Tobacco Exposure on Accelerated Aging See More AI in Biotech Chai Discovery’s $130m bet: can “CAD for molecules” make biologics faster and cheaper? When the FDA Starts Trusting Algorithms: What AIM-NASH Means for Liver Drug Trials The AI science factory arrives: why Lila’s $1.3bn valuation matters beyond biotech AstraZeneca’s $555m Algen bet: why the pharma giant is buying AI-generated targets, not equity How AI is Revolutionizing Antibiotic Discovery to Combat Drug-Resistant Bacteria See More Biotech Stocks Illumina’s Market Struggles Deepen as U.S.-China Tensions Escalate Pharma Giant Eli Lilly to Buy Biotech Firm Morphic for $3.2 Billion Alumis IPO Priced at $16, Targets $210M Funding Diamond Biofund Becomes First Biotech VC Firm Listed on Taiwan Stock Exchange See More CRISPR A one-time gene edit for cholesterol: promise, price and the risks we can’t yet see Intellia’s gene-editing drug faces a liver-safety test as Phase 3 trials pause Base & Prime Editing Move from Hype to Timelines: What Hits Patients 2026–2030? Gene Editing for Everyone: CRISPRware and the Open-Source Biotech Revolution Cholesterol Rewritten: Verve’s Base Editing Therapy May Disrupt a $20B Market See More Food Biotech From Cow-Free Dairy to Human Milk 2.0: Biotechs Race to Brew Breast Milk Proteins Amgen’s $840m wager on Dark Blue shows why pharma keeps paying to make proteins disappear Obesity’s next arms race: staying power, not just weight loss Novartis’s $1.7bn Alzheimer’s bet: the real battleground is the blood–brain barrier Sanofi’s $2.2bn Dynavax deal — and the quiet power of adult vaccines See More Funding The patch that could unstick vaccination: Vaxxas’s A$90m bet on needle-free delivery From Platform to Precision: The $800M Bet Transforming Biotech Investing Draupnir Bio Raises €12 Million to Advance Oral Protein Degraders Targeting Extracellular Proteins Novo Holdings Leads $100 Million Series C Financing for Asceneuron German Biotech CatalYm Raises $150 Million for Phase 2b Cancer Studies See More Genomics From California to Manchester: How One Gene Therapy Is Rewriting Hunter Syndrome Care The hypertension reset: a daily aldosterone blocker meets a twice-yearly gene-silencer Epigenetic Stability Linked to Lifespan in Mammals, Research Show Orna Therapeutics Acquires ReNAgade Therapeutics to Enhance RNA Medicine Development AstraZeneca Completes Equity Investment in Cellectis to Enhance Gene Therapy Development See More Insights Fermenting the Future: Inside the Pentagon’s $80 Million Biomanufacturing Bet—and America’s New Industrial Strategy Beijing’s Biotech Blitz Is Outpacing America. Washington Needs a War Plan. A Champion Departs: Peter Marks’ Resignation and Biotech’s Crossroads From Collapse to Comeback: Inside Biotech’s ‘Death-to-Rebirth’ Cycle Syngene’s Baltimore Bet: Indian Biotech’s American Ambitions and Global Supply Shake-Up See More Longevity The anti-ageing bet on the liver: why longevity biotech’s first real drugs may start here A pill to live to 150? China’s grapeseed longevity hype gets right — and wrong From Crypto to Cytoplasm: Brian Armstrong’s NewLimit Targets Hepatocytes for Anti-Aging Breakthrough Decoding the 100-Year-Old Code: Inside an Ambitious Quest to Unveil the Genetics of Extreme Longevity The Billionaire Longevity Experiment: A Cruise Ship Promises to Extend Life—For a Price See More M&A & Partnerships Amgen’s $840m wager on Dark Blue shows why pharma keeps paying to make proteins disappear Novartis’s $1.7bn Alzheimer’s bet: the real battleground is the blood–brain barrier Sanofi’s $2.2bn Dynavax deal — and the quiet power of adult vaccines Pfizer’s $4.9bn Metsera bet: can amylin finally tame GLP-1’s ‘GI tax’? More Than a Shot: Sanofi’s Vicebio Deal Shows the Power of Platform Biotech See More Neuroscience €132M for a Dutch Rare-Disease Upstart: Is Europe Quietly Becoming the New Neurology Capital? Breaking Barriers: BioArctic’s Blood-Brain Transport Technology and Its Impact on Neurological Drug Delivery Innovative Study on Addiction by Mount Sinai and Rockefeller University See More News The FDA wants to “pre-check” factories before the medicine exists Obesity’s next arms race: staying power, not just weight loss The GLP-1 pill arrives: Novo’s oral Wegovy reshapes the obesity market The obesity wars go to court: Pfizer says Novo’s Metsera bid is a moat, not a merger Galapagos quits cell therapy. Europe’s CGT reckoning begins. See More
Fermenting the Future: Inside the Pentagon’s $80 Million Biomanufacturing Bet—and America’s New Industrial Strategy
Decoding the 100-Year-Old Code: Inside an Ambitious Quest to Unveil the Genetics of Extreme Longevity
Michigan-Based Biotech Startup CircNova Secures $3.3M Seed Funding to Advance AI-Driven Circular RNA Therapies
Michigan-Based Biotech Startup CircNova Secures $3.3M Seed Funding to Advance AI-Driven Circular RNA Therapies
Fermenting the Future: Inside the Pentagon’s $80 Million Biomanufacturing Bet—and America’s New Industrial Strategy
Decoding the 100-Year-Old Code: Inside an Ambitious Quest to Unveil the Genetics of Extreme Longevity
Breaking Barriers: BioArctic’s Blood-Brain Transport Technology and Its Impact on Neurological Drug Delivery
